Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nedosiran - Dicerna Pharmaceuticals

Next Previous
Drug Profile

Nedosiran - Dicerna Pharmaceuticals

Alternative Names: DCR PHXC; Nedosiran sodium - Dicerna Pharmaceuticals; Nidosiran; NN-7022; RivflozaTM

Latest Information Update: 26 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Amides; Amino sugars; Drug conjugates; Small interfering RNA; Urologics
  • Mechanism of Action Lactate dehydrogenase 5 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Primary hyperoxaluria type 1
  • Phase III Primary hyperoxaluria

Most Recent Events

  • 22 Jul 2025 Dicerna Pharmaceuticals completes an expanded access trial for Primary hyperoxaluria type 1 (In adolescents, In adults, In children, In the elderly) (SC), before July 2025 (NCT05993416)
  • 05 Feb 2025 Dicerna Pharmaceuticals completes a phase II trial in Primary hyperoxaluria (In children, In infants, In neonates) in Canada, Germany, Italy, Japan, Lebanon, Poland, Spain, Turkey, United Arab Emirates, United Kingdom, USA (SC) (NCT05001269)
  • 02 Oct 2023 Novo Nordisk plans to launch nedosiran for Primary hyperoxaluria type 1 in USA (SC), in early 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top